^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hairy Cell Leukemia |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) + Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Ibrutinib, vemurafenib (with or without rituximab) or moxetumomab pasudotox are appropriate options for progressive disease following second-line therapy.
